

ESTIMANDS AND INTERCURRENT EVENTS

The Right Fit For You.®



The draft ICH E9 (R1) addendum provides a framework for aligning clinical trial objectives with a precisely specified treatment effect of interest: the estimand. For estimand development including strategies for handling intercurrent events, SDC is The Right Fit For You.



Estimand

- › **Translation** of the trial objective into a precise definition of the treatment effect to be estimated, including:
 - › Population of interest
 - › Strategy for handling intercurrent events
 - › Subject level variable (endpoint)
 - › Population level summary of variable
- › **Foundation for Study Design**, estimators (primary & sensitivity), and hypothesis testing in clinical trials

Intercurrent Events (IcE)

- › **Occur After Treatment Initiation** and preclude observation or affect interpretation of the variable
- › **Examples Include** use of a rescue medication, treatment discontinuation, or death
- › **Strategies for Handling** intercurrent events include:

Treatment Policy

The IcE is irrelevant. The value of the variable is used regardless of IcE occurrence.

Composite

The IcE is a component of the variable. For example, if a patient discontinues, the variable is considered a failure.

Hypothetical

What would have happened if the IcE did not occur, such as if the rescue medication was not made available?

Principal Stratum

The target population is the stratum in which an IcE would not occur; e.g. those who are not responsive to rescue treatment

While on Treatment

The response to treatment prior to IcE is of interest. No need to collect measure after treatment discontinuation.

The Right Fit For You.®



SDC is a specialized data services CRO providing scalable full-service clinical trial solutions via our diverse and complementary strategic partnerships. From protocol consulting to full-service clinical trial management and everything in between, SDC is The Right Fit For You.



Clinical Program Design/Development
Regulatory/Submission Guidance
Simulation & Modeling



Biostatistics
Data Management & EDC
IRT/IWRS
DMC/DSMB



Clinical Operations
Medical Writing
Specialty Core Lab

Mini Case Study

- > Phase 1 Single Ascending Dose (SAD) study for safety, efficacy, and pharmacokinetics
- > 8 Cohorts with Safety Review Meetings one week after new cohort dosing
- > Maintained Rapid Turnaround or analysis throughout duration of study

